Beyond Air CEO to Present at Roth Conference Amid Clinical Trial Push
Event summary
- Beyond Air CEO Steve Lisi to participate in fireside chat at Roth Conference on March 23, 2026.
- Company to host one-on-one meetings with investors during the event.
- Beyond Air's LungFit PH system is FDA-approved and CE-marked for treating neonatal respiratory failure.
- Clinical trials ongoing for LungFit systems targeting viral pneumonia and nontuberculous mycobacteria.
- Beyond Cancer affiliate exploring ultra-high NO concentrations for solid tumor treatment.
The big picture
Beyond Air's participation in the Roth Conference comes as it seeks to diversify its revenue streams beyond its approved LungFit PH system. The company is positioning itself at the intersection of medical device innovation and biopharmaceutical applications of nitric oxide, a space gaining traction as respiratory and oncology indications expand. Its ability to secure investor confidence will be critical as it navigates the capital-intensive phase of clinical development.
What we're watching
- Clinical Progress
- The pace at which Beyond Air advances its LungFit systems through clinical trials for pneumonia and NTM treatments will determine its commercial expansion beyond neonatal care.
- Regulatory Strategy
- Whether Beyond Air can leverage its existing FDA and CE approvals to accelerate regulatory pathways for its other nitric oxide-based therapies.
- Investor Sentiment
- How investor discussions at the Roth Conference may impact Beyond Air's valuation as it transitions from a single-approved product to a broader pipeline.
Related topics